Table 2.
Ongoing clinical trials evaluating agents targeting hedgehog signaling pathway.
| Agent | Tumor Types | Phase of Development | Clinicaltrials.Gov Identifier |
|---|---|---|---|
| BMS-833923 | Advanced or metastatic cancer | I | NCT00670189 |
| Extensive stage small cell lung cancer | I: carboplatin, etoposide and BMS-833923 | NCT00927875 | |
| Metastatic gastric, gastroesophageal, or esophageal adenocarcinomas | I: BMS-833923, cisplatin and capecitabine | NCT00909402 | |
| Itraconazole | Esophageal cancer | I | NCT02749513 |
| Prostate cancer | II | NCT01787331 | |
| Skin basal cell carcinoma | I | NCT02735356 | |
| Non-small cell lung cancer | II: itraconazole and chemotherapy | NCT03664115 | |
| Non-small cell lung cancer | I: neoadjuvant setting | NCT02357836 | |
| Basal cell carcinoma | II: SUBA-Itraconazole | NCT02354261 | |
| Various tumors | I: volasertib and itraconazole | NCT01772563 | |
| Glioblastoma | I: itraconazole and temozolomide | NCT02770378 | |
| Saridegib | Recurrent head and neck cancer | I: saridegib and cetuximab | NCT01255800 |
| Metastatic solid tumor | I | NCT00761696 | |
| Metastatic pancreatic cancer | I/II: saridegib and gemcitabine | NCT01130142 | |
| Advanced chondrosarcoma | II: saridegib or placebo | NCT01310816 | |
| Sonidegib | Advanced or metastatic hepatocellular carcinoma | I | NCT02151864 |
| Basal cell carcinoma | II: neoadjuvant sonidegib followed by surgery or imiquimod | NCT03534947 | |
| Extensive stage small cell lung cancer | I: sonidegib, etoposide and cisplatin | NCT01579929 | |
| Resectable pancreatic adenocarcinoma | I/II: sonidegib, gemcitabine, nab-paclitaxel in neoadjuvant setting | NCT01431794 | |
| Localized prostate cancer | I | NCT02111187 | |
| Multiple myeloma | II: sonidegib and lenalidomide | NCT02086552 | |
| Esophageal cancer | I: sonidegib and everolimus | NCT02138929 | |
| Advanced pancreatic cancer | I: sonidegib, fluorouracil, leucovorin, oxaliplatin, irinotecan | NCT01485744 | |
| Pancreatic cancer | I/II: sonidegib, gemcitabine, and nab-paclitaxel | NCT02358161 | |
| Advanced solid tumor | I | NCT01208831 | |
| Advanced solid tumor | I | NCT00880308 | |
| Solid tumors | I: sonidegib and paclitaxel | NCT01954355 | |
| Advanced solid tumors | I: sonidegib and BKM120 | NCT01576666 | |
| Myeloid malignancies | I: sonidegib with azacytidine or decitabine | NCT02129101 | |
| Advanced or metastatic basal cell carcinoma | II: sonidegib and buparlisib | NCT02303041 | |
| LEQ-506 | Advanced solid tumors | I | NCT01106508 |
| Taladegib | Advanced cancers | I | NCT01919398 |
| Esophageal cancer | I/II: Taladegib, paclitaxel, carboplatin, and radiation | NCT02530437 | |
| Advanced solid tumors | I | NCT02784795 | |
| Glasdegib | Hematologic malignancies | I | NCT00953758 |
| Solid tumors | I | NCT01286467 | |
| Acute myeloid leukemia | II | NCT01841333 | |
| Hematologic malignancies | I: with standard chemotherapy agents | NCT02038777 | |
| Acute myeloid leukemia | III: chemotherapy or azacytidine with or without glasdegib | NCT03416179 | |
| Glioblastoma | I/II: glasdegib and temozolomide | NCT03466450 | |
| TAK-441 | Advanced nonhematologic malignancies | I | NCT01204073 |
| Vismodegib | Metastatic pancreatic adenocarcinoma | II: vismodegib, gemcitabine and nab-paclitaxel | NCT01088815 |
| Solid and hematologic malignancies | II: Canadian profiling and targeted agent utilization trial | NCT03297606 | |
| Keratocystic odontogenic tumors | II | NCT02366312 | |
| Acute myeloid leukemia | II: ribavirin, vismodegib with or without decitabine | NCT02073838 | |
| Pancreatic adenocarcinoma | I: vismodegib and gemcitabine in neoadjuvant setting | NCT01713218 | |
| Basal cell nevus syndrome, Gorlin syndrome | II | NCT00957229 | |
| Breast cancer | II: neoadjuvant paclitaxel, epirubicin, cyclophosphamide with or without vismodegib | NCT02694224 | |
| Glioblastoma | I/II: Neuro Master Match | NCT03158389 | |
| Recurrent medulloblastoma | I | NCT00822458 | |
| Metastatic pancreatic cancer or solid tumors | I: vismodegib, erlotinib, and gemcitabine | NCT00878163 | |
| Advanced chondrosarcoma | Phase 1 | NCT01267955 | |
| Advanced basal cell skin cancer | I/II: pembrolizumab with or without vismodegib | NCT02690948 | |
| Advanced solid tumors | II: My Pathway | NCT02091141 | |
| Advanced head/neck basal cell carcinoma | II: vismodegib and radiation | NCT01835626 | |
| Advanced gastric cancer | II | NCT03052478 | |
| Multiple myeloma | I | NCT01330173 | |
| Solid tumors, lymphomas or multiple myeloma | II: MATCH | NCT02465060 | |
| Orbital and periocular basal cell carcinoma | IV | NCT02436408 | |
| Medulloblastoma | II: with radiation and chemotherapy | NCT01878617 | |
| Vitamin D3 | Basal cell carcinoma | I: with photodynamic therapy | NCT03483441 |
| Pancreatic cancer | III: high dose versus standard dose | NCT03472833 | |
| Acute myeloid leukemia | II: deferasirox, vitamin D3, and azacitidine | NCT02341495 | |
| Chronic lymphocytic leukemia, non-Hodgkin lymphoma | I | NCT02553447 | |
| Indolent lymphoma | III: rituximab with or without vitamin D3 | NCT03078855 | |
| Arsenic trioxide | High-grade glioma | I: with temozolomide and radiation therapy | NCT00720564 |
| Glioma | I: with radiation therapy | NCT00095771 | |
| Glioma | I: stereotactic radiotherapy | NCT00185861 | |
| Neuroblastoma and other childhood solid tumors | II | NCT00024258 | |
| Basal cell carcinoma | I/II | NCT01791894 |